photo of immunotherapy vial

The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diagnosed non-small cell lung cancers (NSCLC), which comprise up to 85% of all lung tumors.



from WebMD Health https://ift.tt/2GoGlJ9

Related Posts:

  • Anti-Vaxxers' Son Who Got Measles Speaks Out The man ended up in isolation at a hospital and at one point became so weak that he couldn't walk without assistance. He lost 25 pounds and it took months for him to fully recover. from WebMD Health https://ift.tt/2EBNS2o … Read More
  • Heart Attacks Striking More Young Adults These young heart attack victims also have the same risks of dying from another heart attack or stroke as older patients. from WebMD Health https://ift.tt/2XCAiVg … Read More
  • HRT Linked to Slight Rise in Alzheimer's Risk The study found that women taking hormone replacement therapy had a 9 percent to 17 percent higher risk of developing Alzheimer's disease. In women who began taking hormone therapy before age 60, this increased risk was tied… Read More
  • High Testosterone Level Bad News for the Heart Although the study focuses on men with naturally high testosterone, it has implications for aging men who are taking testosterone supplements to boost their energy levels and improve their sex drive, experts said. from Web… Read More
  • Hidden FDA Reports Show Harm From Medical Devices The Food and Drug Administration has let medical device companies file reports of injuries and malfunctions outside a widely scrutinized public database, leaving doctors and medical sleuths in the dark. from WebMD Health h… Read More

0 comments:

Post a Comment

Popular Posts